🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Struggling to read – such as when cooking, paying bills or driving – could be a sign of geographic atrophy (GA). Encouraging your loved one to receive regular eye exams may help detect GA earlier. ​ Learn more: bit.ly/4l8Csqi​ For U.S. Audiences Only

Astellas has announced a collaboration with the Japanese Foundation for Cancer Research to accelerate translational and clinical oncology research. We look forward to working with this world-class comprehensive cancer research center. Learn more: bit.ly/41WwfGK

The Astellas team is heading to ARVO and RWC! We're excited to present data featuring analyses on geographic atrophy biomarkers, patient experience and more.​ Learn about the data we're sharing: bit.ly/3EOfc0z​ #ARVO2025 #RetinaWorldCongress ​ For U.S. audiences only

Our team is on the ground in Salt Lake City and excited to kick off the ARVO Annual Meeting. Stop by the Astellas booth (#1925) to learn about our new data in geographic atrophy biomarkers, mechanism of disease and more. #ARVO2025 For U.S. audiences only

When it comes to #BladderCancer, knowing what to look for—and when to speak up—can lead to earlier diagnosis and potentially better outcomes. This #BladderCancerAwarenessMonth, learn more about risk factors, symptoms, and more: bit.ly/4iMj7sI

For Army veteran Dan, his time serving equipped him with the skills needed to take on a new fight: #ProstateCancer. We’re thankful for Dan, his service, and his willingness to share his story so that others facing prostate cancer don’t feel alone. #MilitaryAppreciationMonth

We had a great week discussing the latest geographic atrophy insights with the retina community at ARVO Annual Meeting. We’re already looking forward to next year! #ARVO2025 For U.S. audiences only

In honor of Global Accessibility Awareness Day, we are sharing pointers from Sam Seavey, low vision expert, on how to keep accessibility top of mind. Improving accessibility is key to ensuring all patients can access care and resources. #GAAD #VisionLoss For U.S. Audiences Only

We’re excited to be presenting data at @ACOG 2025 here in Minneapolis. Improving patient outcomes is a critical focus of ours, particularly through research and education, so be sure to visit us at booth #1011 to learn more about our latest advancements in women’s health! #ACOG25

At Astellas, we’re pushing the boundaries of cancer treatment. See what we’ll be sharing at #ASCO25: bit.ly/45edwZ1

Bladder cancer symptoms don’t always look the same in men and women—and that can lead to missed or delayed diagnoses, especially in women. During #BladderCancerAwarenessMonth, learn more about the importance of recognizing signs and taking action early: bit.ly/44Lr7ac

In honor of Mental Health Awareness Month, we’re partnering with BrightFocus Foundation for a Macular Chat to discuss the impact of vision loss on mental health and the emotional challenges faced by those with low vision. Register here: bit.ly/43a1Q8k For U.S. Audiences Only

Now available: overall survival updates in metastatic hormone-sensitive #ProstateCancer. bit.ly/43tnB1E We're excited to build on our 10-year+ commitment to this community and help drive progress for those with hormone-sensitive disease. #ASCO25 For U.S. audiences only

Ahead of #ASCO25, our Chief R&D Officer, Tadaaki Taniguchi, shared with FiercePharma how Astellas is harnessing new therapeutic approaches and technologies to change the future of #cancer care. Read the article here: bit.ly/4mzAJLA #ChangingTomorrow

#ASCO25 starts tomorrow! We are proud to share our commitment to impacting the cancer treatment landscape with our latest oncology research.  #ProstateCancer #BladderCancer #GastricCancer #AML

We’re pleased to share that Astellas has entered into an exclusive license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage #ADC targeting CLDN18.2. Learn more: bit.ly/3Z7zjOo

Patient Advocacy Organization (PAO) Action Week returns next week for its second year! This collaborative initiative is dedicated to raising awareness and connecting patients to relevant PAOs. Follow #PAOActionWeek and visit bit.ly/3HbdIhT for more info.

Today at #ASCO25: Dr. Andrew Armstrong (@AArmstrongDuke) is presenting updates from our research in metastatic hormone-sensitive #ProstateCancer, conducted in partnership with @Pfizer. See more: bit.ly/43tnB1E For U.S. audiences only.